Each case had data from a 447-gene targeting exome sequencing assay, chromosomal copy-number analysis, and O6-methylguanine-DNA methyltransferase (MGMT) promoter analysis; MGMT silencing is predictive of glioblastoma sensitivity to alkylating chemotherapy58. This evidence concerns the gene MGMT and glioblastoma.